Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Canadian Pricing Body Sharpens Its Teeth

This article was originally published in Scrip

Executive Summary

Companies doing business in Canada are likely to see new action to drive down medicine prices. Concerned by spiraling drug prices and its place in an increasingly complex pricing and reimbursement environment, the Patented Medicine Prices Review Board (PMPRB) has published a new three-year strategic plan which will address how it can better contribute to lower prices and sustainable healthcare, although nearer-term measures could be on the cards too.

Advertisement

Related Content

Canada Plans To Force Firms To Disclose Confidential Pricing Deals
Canada Plans Drug Price Reductions By Changing Reference Country List

Topics

Advertisement
UsernamePublicRestriction

Register

SC064164

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel